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Abstract
The Smoothened receptor (SMO) mediates signal transduction in the hedgehog pathway, which is
implicated in normal development and carcinogenesis. SMO antagonists can suppress the growth
of some tumors; however, mutations at SMO have been found to abolish their anti-tumor effects, a
phenomenon known as chemoresistance. Here we report three crystal structures of human SMO
bound to the antagonists SANT1 and Anta XV, and the agonist, SAG1.5, at 2.6–2.8Å resolution.
The long and narrow cavity in the transmembrane domain of SMO harbors multiple ligand
binding sites, where SANT1 binds at a deeper site as compared with other ligands. Distinct
interactions at D4736.55 elucidated the structural basis for the differential effects of
chemoresistance mutations on SMO antagonists. The agonist SAG1.5 induces a conformational
rearrangement of the binding pocket residues, which could contribute to SMO activation.
Collectively, these studies reveal the structural basis for the modulation of SMO by small
molecules.
Introduction
The hedgehog (Hh) signal transduction network plays essential roles in the maintenance of
normal embryonic development and postnatal tissue integrity in many eukaryotes ranging
from Drosophila to humans 1,2. Aberrant activation of the Hh signaling pathway apparently
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both promotes carcinogenesis–particularly in basal cell carcinomas and medulloblastomas–
and supports the tumor microenvironment in many other cancers 3. The smoothened receptor
(SMO) belongs to the Class Frizzled (or Class F) receptors, which is part of the G protein-
coupled receptor (GPCR) superfamily. SMO is normally negatively regulated by a catalytic
amount of the 12-transmembrane domain protein Patched 4. In the vertebrate canonical Hh
signaling pathway, the binding of the Hh signaling proteins to Patched can induce the
translocation of SMO to primary cilium, thereby inducing the processing of GLI
transcription factors into their active forms, which subsequently undergo nuclear
translocation and activate GLI targeted genes 2. It has been proposed that Patched acts as a
transporter and controls SMO activity by controlling the availability of small molecule lipid
modulators of SMO 4. Although the identity of the endogenous small molecule modulator of
SMO is unknown, a number of exogenous small molecules that modulate SMO activity have
been discovered 5. Notably, the naturally occurring teratogen cyclopamine, which was the
first selective SMO ligand, inhibits Hh signaling presumably via SMO antagonism by
targeting to its 7-transmembrane (7TM) domain6. Given the importance of inhibiting Hh
signaling pathways in various cancers, small molecules that target SMO are under intensive
development and several lead compounds are currently in clinical trials, including
Vismodegib (GDC-0449, Supplementary Figure 1) which was approved by the U.S. Food
and Drug Administration (FDA) in 2012 for treating basal cell carcinoma 7,8.
Despite the tremendous progress in explicating SMO pharmacology and the recent success
in obtaining the first human SMO structure 9, a molecular understanding of the structural
basis for small molecule recognition of SMO remains elusive. This is not only important for
understanding the structure-activity relationships (SAR) of chemically distinct SMO ligands,
but also for providing a mechanistic understanding of chemoresistant mutations. For
example, the D4736.55H (superscripts indicate residue numbering using the Ballesteros-
Weinstein nomenclature for class F receptors 9,10) mutation in human SMO makes
antagonists such as GDC-0449 unable to inhibit the receptor 11; while several other
compounds are insensitive to this drug resistance mutation 12–14. Delineating the structural
basis for the differential effects of mutations on diverse ligands would provide a rational
platform for the development of drugs to counteract emerging drug resistance effects.
Additionally, the modulation of SMO by small molecules reveals complicated effects on
ligand efficacy. For example, SAG (3-chloro-N-[4-(methylamino)cyclohexyl]-N-[3-
(pyridin-4-yl)benzyl]benzo[b]thiophene-2-carboxamide) 15,16 and derivatives including
SAG1.5 (3-chloro-4,7-difluoro-N-[trans-4-(methylamino)cyclohexyl]-N-[[3-(4-
pyridinyl)phenyl]methyl]-1-benzothiophene-2-carboxamide) 16 (Supplementary Figure 1)
act as potent agonists, inducing cilia translocation of SMO and GLI transcription factor
activation. Cyclopamine and SANT1 (N-[(1E)-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-
yl)methylidene]-4-(phenylmethyl)-1-piperazinamine) 15 (Supplementary Figure 1), for
instance, both inhibit GLI transcription factor activation, while SANT1 inhibits and
cyclopamine induces cilia translocation of SMO 17. In addition, molecules such as
cyclopamine and GDC-0449, which were initially discovered as potent antagonists for the
canonical Hh signaling pathway, act as agonists to induce the glucose uptake response and
drive Warburg-like metabolism in fat and muscle cells via a transcription factor independent
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pathway 18, perhaps accounting for the unwanted side effects of weight loss and muscle
cramping observed in humans. Clearly, determining the binding modes of different ligands
to SMO represents an essential first step for correlating a ligand’s chemotype with its pattern
of functional modulation, thereby illuminating the pharmacology and biology of SMO.
In this study, we report three crystal structures of the human SMO 7TM domain bound to
SMO small molecule antagonists SANT1, Anta XV (2-(6-(4-(4-benzylphthalazin-1-
yl)piperazin-1-yl)pyridin-3-yl)propan-2-ol) 19 and agonist SAG1.5 (Supplementary Figure
1). Structure-guided mutagenesis and competition binding analysis probed the specific
effects of key amino acid residues in these structures. A further examination of these
structures alongside the structures of the human SMO in complex with LY2940680 9 and
cyclopamine 20 provides a comprehensive framework for understanding the structural basis
of molecular recognition and modulation at SMO by small molecules.
Results
Crystallization and structures of SMO-ligand complexes
To investigate the structural basis of activation and inhibition of SMO, we solved the
structure of SMO in complex with ligands of different functional properties including the
antagonists SANT1 and Anta XV, and the potent agonist SAG1.5. Using the previously
reported SMO construct 9 with the N-terminal cysteine-rich domain (CRD, residues 1–189)
replaced by a thermostabilized apocytochrome b562RIL (BRIL), and a truncated C-terminus
at Q555 (BRIL-ΔCRD-SMO-ΔC), we obtained crystals of SMO bound to SANT1, Anta XV
and SAG1.5. The structure of the SMO_SANT1 complex was solved at 2.8 Å resolution in a
C2221 space group (Table 1). However, initial crystals of SMO with Anta XV and SAG1.5
diffracted to only 3.5 Å and 8 Å, respectively. In order to improve the resolution of the Anta
XV and SAG1.5 bound SMO complexes, we applied another fusion strategy by replacing
intracellular loop 3 (ICL3, from P434 to K440) with BRIL (ΔCRD-SMO-BRIL(ICL3)-ΔC).
Using this construct, the structure of the SMO_Anta XV complex was solved in a P212121
space group at 2.6 Å resolution; the structure of the SMO_SAG1.5 complex was solved in a
C2 space group with resolution cut-off at 2.9Å, 2.5 Å and 3.3 Å along a*, b* and c* axes,
respectively, due to the anisotropic nature of the diffraction (Table 1). In addition, we have
solved the SMO_cyclopamine complex structure (PDB id: 4O9R) using a newly developed
technique of serial femtosecond crystallography with LCP grown crystals (LCP-SFX) at an
X-ray free electron laser source. Albeit at a lower resolution, this structure unambiguously
located the binding site of cyclopamine 20. The crystal packing analysis (Supplementary
Figure 2) reveals that the SMO_SANT1, SMO_Anta XV and SMO_cyclopamine complexes
were crystallized as monomers, while the SMO_SAG1.5 complex was crystallized as a
dimer, similar to the previously reported SMO_LY2940680 complex 9 (PDB id: 4JKV),
with a dimer interface involving helices IV and V.
Along with the SMO_LY2940680 and SMO_cyclopamine complex structures, the newly
solved structures show that the long and narrow cavity formed by the extracellular domain
(ECD) linker domain, extracellular loops and the 7TM bundle provides multiple binding
sites for small molecule ligands (Fig. 1 and Supplementary Figure 3). Similar to LY2940680
and cyclopamine, the binding sites of Anta XV and SAG1.5 are formed mostly by residues
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from the ECD linker domain and extracellular loops (Fig. 1d,f). Additionally, Anta XV,
SAG1.5 and LY2940680 form hydrogen bonds with the N219ECD side chain, which
provides an important anchor for ligands that bind close to the entrance of the ligand binding
cavity. In contrast, SANT1 binds at a unique site in the cavity, which extends much deeper
toward the center of the 7TM bundle and is formed mainly by residues from all the
transmembrane α-helices, with the exception of helix IV (Fig. 1b).
The deep binding site of SANT1
The binding site of SANT1 is unusually deep in the 7TM helical bundle, with the ligand
extending at least 9 Å deeper into the cavity compared to LY2940680 (Fig. 2a). The only
extracellular loop that interacts with SANT1 is extracellular loop 2 (ECL2), which is
positioned inside the helical bundle and forms non-polar contacts and a hydrogen bond from
Y394ECL2 to the phenyl ring and the pyrazole ring of SANT1, respectively (Fig. 1b). In the
helical bundle, this binding pocket is very narrow, providing a snug fit for the long and
linear structure of SANT1. The side chain of H4706.52 forms a hydrogen bond to a nitrogen
in the piperazine ring (Fig. 1b). Superposition of the SMO_SANT1 and the SMO_SAG1.5
structures (Fig. 2a) reveals only a minimal overlay between SANT1 and SAG1.5, thereby
providing a structural explanation for previous observations that SANT1 allosterically
modulates the binding of SAG 21, which is a close derivative of SAG1.5 (Supplementary
Figure 1). In the SMO_SANT1 complex, the compound induces a slight expansion in the
deep part of the cavity, as compared to the other ligands that do not reach this sub-pocket
(Fig. 2b,c). This change in the pocket is manifested mainly in a conformational
rearrangement of the side chains, while minimally affecting the protein backbone. The side
chain of L3253.36 protrudes into the central cavity when this deep pocket is not occupied,
but rotates out from the cavity making space for the binding of SANT1 (Fig. 2d).
Additionally, the side chain of M5257.45 moves towards SANT1 to make contact with the
piperazine moiety of the ligand. To further investigate the binding pocket for SANT1, we
introduced bulky side chain mutations, L3253.36F, V3293.40F, I4085.47F and T4666.48Q, in
the bottom part of the pocket (Fig. 2d), aiming to block this binding site without disturbing
the overall receptor conformation. While the binding of the radioligand 3H-cyclopamine
remains unchanged in agreement with the SMO_cyclopamine structure, competition
radioligand binding experiments reveals that three of these bulky mutations, V3293.40F,
I4085.47F and T4666.48Q, substantially reduce the binding of SANT1 (Fig. 2e and
Supplementary Table 1). Interestingly, the L3253.36F mutation has no effect on SANT1
binding, consistent with the modeling of the L3253.36F mutation which shows that the
SMO_SANT1 complex can easily accommodate a phenyl side chain in the rotamer state
observed for L3253.36 in the SANT1 bound structure (Fig. 2d). Binding of the other tested
ligands was not substantially affected by any of these bulky side chain mutations (Fig. 2e),
corroborating the unique nature of the deep binding site for SANT1 among the other SMO
ligands studied.
The binding mode of cyclopamine and KAAD-cyclopamine
The naturally occurring steroidal jerveratrum alkaloid cyclopamine was the first small
molecule found to bind to and inhibit Hh signaling via SMO. Cyclopamine binds close to
the extracellular entrance, and the secondary amine of its 3-methyl-piperidine group points
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outside of the pocket, while the 3,β-hydroxyl is buried deep in the pocket (Supplementary
Figure 4a) 20. This binding pose is consistent with previous SAR studies of cyclopamine
derivatives, which showed that adducts to the 3,β-hydroxyl dramatically reduced activity,
while the secondary amine permits addition of bulky groups via long aliphatic linkers 22.
One such molecule is KAAD-cyclopamine (3-keto-N-(aminoethyl-aminocaproyl-
dihydrocinnamoyl)cyclopamine) (Supplementary Figure 1), derived by attaching a long
chain substitution to the secondary amine of cyclopamine. Our data shows that the binding
of KAAD-cyclopamine to SMO is not impacted by mutations blocking the deep binding
pocket (Fig. 2e), consistent with a predicted binding mode where the long chain substitution
extends out of the 7TM cavity through the extracellular ligand entrance (Supplementary
Figure 4b). The long aliphatic linker protruding out of the pocket has also been shown to
enable attachments as large as a fluorescent BODIPY moiety to cyclopamine 6.
Differential binding modes of Anta XV and LY2940680
Although Anta XV and LY2940680 share a phthalazine ring core and a similar overall
shape, different substitutions on the phthalazine ring result in distinct binding modes of
these ligands. In the previously solved SMO_LY2940680 structure 9, the 4-fluoro-2-
trifluoromethylphenyl moiety of LY2940680 forms extensive interactions with residues
from ECL3, including Q477, W480, E481 and F484, which stacks to the phenyl ring of
LY2940680 through a π-π interaction (Fig. 3a). In contrast, Anta XV does not have contacts
with ECL3, and the side chain residue conformations of ECL3 in the SMO_Anta XV
structure are more similar to those in the structure of SMO_SANT1, which also lacks ECL3
contacts (Supplementary Figure 5). The differential interaction of LY2940680 with ECL3
apparently results in an overall shift of the α-helical portion of the ECL3 (Fig. 3b,c).
Together with the extensive interactions between the 4-fluoro-2-trifluoromethylphenyl
group of LY2940680 and ECL3, the hydrogen bond between N219 and the carbonyl group
of LY2940680 potentially defines the orientation of piperidine ring substituent on the
phthalazine core, which is distinct from the orientation of the piperazine of Anta XV (Fig.
3d). In this orientation, the phthalazine core of LY2940680 adopts an axial position in the
chair conformation of the six-membered piperidine ring, which was estimated to be slightly
(ΔE~0.72 kcal/mol) 23 suboptimal compared to the equatorial position. In contrast, on the
piperazine ring of Anta XV, the phthalazine core sits in the equatorial position; this
difference in ring conformation is accompanied by a 1 Å shift of the phthalazine ring
between the two ligands (Fig. 3d). The shift is also associated with a shift at the guanidinium
group of R4005.39, which forms hydrogen bond to the phthalazine core of Anta XV and
LY2940680, as well as the extracellular end of helix V where R4005.39 locates (Fig. 3e–g).
This difference in the positions of the phthalazine core in Anta XV and LY2940680 may
explain their distinctive interactions with D4736.55, a key residue in a polar interaction
cluster within the ligand binding cavity (Figs. 3c,i). Firstly, the side chain of D4736.55 makes
a direct interaction with Anta XV (3.3 Å) whereas its interaction with LY2940680 is much
weaker as revealed by a longer distance (4.0 Å in molecule A, 4.3 Å in molecule B).
Secondly, the interaction between D4736.55 and Anta XV is accompanied by an inward shift
of the extracellular tip of helix VI, as compared to SMO_SANT1 and SMO_LY2940680
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structures where their respective ligands do not interact with D4736.55 (Fig. 3e–g). The
difference in this interaction is also reflected in different rotamer states of the carboxylate
group of D4736.55 (Fig. 3h). All these structural data point to a more important role for
D4736.55 in Anta XV recognition compared to LY2940680.
Mutation of D4736.55 into histidine has been identified as a cause of chemoresistance for
GDC-0449, while LY2940680 has been reported to be unaffected by this mutation 24. To
investigate the role of D4736.55 in the binding of different ligands, we performed 3H-
cyclopamine competition binding assays on a D4736.55A mutant, as well as an E5187.38A
mutant that could impact the conformation of D4736.55. The natural drug-resistance
mutation D4736.55H and other mutations that could impact the conformation of D4736.55,
such as R4005.39A, H4706.52A, and N5217.41A (Fig. 3h), unfortunately could not be
assessed in the radioligand competition assay, as they abolished the binding of
radioligand 3H-cyclopamine. Among the mutations that retained binding of the radioligand,
the D4736.55A and E5187.38A mutations impaired the binding of GDC-0449 and Anta XV,
with D4736.55A responsible for a more than 100 fold affinity drop for both ligands. In
contrast, the effect of D4736.55A mutation on LY2940680 was modest (<7 fold), consistent
with the lack of such a direct interaction in the SMO_LY2940680 structure (Fig. 3j and
Supplementary Table 2). Moreover, these mutations have no effect on the binding of
SANT1, consistent with the fact that in the SMO_SANT1 structure D4736.55 plays little role
in ligand binding. These results thus provide a direct structural explanation for the
differential effect of ligand binding pocket mutations on ligands with distinct binding poses.
Remodeling of the SMO binding pocket by agonist SAG1.5
When bound to SMO, the two aromatic rings of SAG1.5 pack against each other, forming a
bulky system that fits tightly into the pocket surrounded by the ECD linker domain and
extracellular loops close to the extracellular entrance (Fig. 1f). This clamping of the bulky
aromatic groups of SAG1.5 by the extracellular loop structures points the cyclohexane
deeper into the 7TM bundle, aligning the positively charged methyl amino group in the
vicinity of polar residue cluster, R4005.39, D4736.55 and E5187.38 (Figs. 1f and 4), which are
the only residues from the seven helixes that interact with the agonist. In the antagonist
bound structures, the D4736.55 and E5187.38 side chains point towards each other and
interact directly, or in the case of the SMO_LY2940680 structure, through water mediated
interactions. In the agonist bound structure, the positively charged amino group of SAG1.5
forms an ionic interaction with D4736.55, while the carboxyl group of E5187.38 moves away
and no longer interacts with D4736.55 (Fig. 4a). In the antagonist bound structures, R4005.39
is anchored by polar interactions with D4736.55, H4706.52 and/or the ligands. In the agonist
bound structure, the guanidine group of R4005.39 moves up to form a hydrogen bond with
the side chain of Q477ECL3 (Fig. 4b). This remodeling at the residues R4005.39, D4736.55
and E5187.38 (Fig. 4c) is the most pronounced change in the ligand binding pocket,
differentiating the SMO_SAG1.5 structure from the antagonist-bound structures. In
addition, subtle modifications at the amino group of the SAG scaffold have been shown to
change the functional property of the ligand, i.e. from agonist to antagonist 25, indicating
that this amino group plays a critical role in the SMO modulation by SAG1.5. While
previous studies showed that oxysterol binding at the N terminus of SMO can induce
Wang et al. Page 6






















activation 26–28, the SAG1.5 bound SMO structure reveals an alternative site at the 7TM
domain that is responsible for the small molecule induced activation of the receptor (Fig. 5).
On the intracellular side, the most pronounced difference between agonist and antagonist
bound structures is observed at Y262ICL1, H3614.46 and W3654.50 that are conserved among
class F receptors 9. In all the antagonist bound structures, we observed a hydrogen bonding
network among these residues. In the agonist bound structure, the hydrogen bond between
Y262ICL1 and H3614.46 is broken, which is associated with an inward movement of
P263ICL1, which is also conserved among class F receptors 9, to make contact with
W5357.55 (Supplementary Figure 6). Mutation of W5357.55 into leucine has been shown to
make the SMO receptor constitutively active leading to carcinogenesis 29. In addition,
W5357.55 is located at the intracellular end of helix VII, immediately adjacent to helix VIII
(Supplementary Figure 6), which packs against helix I, parallel to the membrane layer and
plays an important role during the activation of SMO since mutation at the residues W545
and R546 located in helix VIII impairs cilia translocation 30. These conformational changes
observed at Y262ICL1, H3614.46, W3654.50 and P263ICL1 could impact W5357.55, and are
conceivably important for SMO activation. We note however that the change of the
hydrogen bond state could result from the slightly lower pH in the crystallization condition
of the agonist bound receptor. Thus, the involvement of this conformational change during
SMO activation needs to be investigated in future studies. With the exception of this local
conformational change, the agonist SAG1.5 bound SMO structure does not show any large
scale movements in helices VI and VII, which are the hallmark of class A GPCR
activation 31. This may be due to the stark differences in signaling mechanisms between the
two GPCR classes, or the possibility that in the absence of downstream effectors SAG1.5
induces only part of the activation-related conformational changes in SMO or other factors
(Discussion).
Discussion
The newly solved structures of SMO bound to SANT1, Anta XV, SAG1.5, along with the
LY2940680 and cyclopamine bound structures, reveal a variety of distinctive poses for
structurally diverse small molecule ligands in the long and narrow cavity defined by the
7TM helices, ECD and extracellular loops of SMO (Fig. 5). The antagonist SANT1, for
instance, binds very deep in the pocket, whereas the other ligands studied remain closer to
the extracellular entrance, demonstrating that the entire long and narrow pocket can be
targeted by small molecule ligands. Meanwhile, the extracellular entrance can provide a path
for accommodating the attachment of reporter moieties or other bulky groups to the ligands
through a long chain flexible linker such as that of KAAD-cyclopamine.
Even when the binding sites largely overlap, as for instance with LY2940680 and Anta XV,
minor differences in recognition modes result in a discrete response to binding pocket
mutations. LY2940680, for example, has been reported to bind the D4736.55H mutant that
provides chemoresistance to the approved cancer drug GDC-0449 24. This biological
phenomenon accords nicely with our structural analysis, which shows that LY2940680
forms weak interactions with D4736.55. In contrast, the binding of Anta XV requires a more
substantial involvement of D4736.55, as revealed by the structural and mutagenesis data,
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despite its similar scaffold with LY2940680. The most striking difference between the
binding mode of LY2940680 and Anta XV is a strong interaction between LY2940680 and
ECL3. We hypothesize that this interaction restrains the orientation of LY2940680, which
leads to a shift of the phthalazine core of LY2940680 away from D4736.55 compared to Anta
XV, weakening the role of D4736.55 in ligand binding. This reduced involvement of
D4736.55 in binding might also underlie the effect of chemical modifications on existing
compounds which could overcome the drug resistant mutation D4736.55H as shown in
studies with derivatives of GDC-0449 12 and Anta XV 14. The long and continuous cavity
straddling the ECL region and 7TM domain of SMO provides a variety of binding sub-sites
suitable for ligand interaction. Taken together, this structural information should facilitate
the development of compounds, which bypass this chemoresistant mutation or have a larger
contacting surface so that disruption of a local structure, as chemoresistance mutations do,
could not abolish the ligand binding.
We observed remodeling of the polar interaction network between R4005.39, D4736.55 and
E5187.38 in the binding pocket induced by SAG1.5; such remodeling could conceivably
serve as an activation trigger. However, due to the lack of knowledge regarding the
immediate biochemical events downstream of SMO 7TM domain activation, a mechanistic
connection between the ligand-triggered activation at the extracellular side and the
intracellular coupling with downstream proteins remains to be established. SMO has shown
in some studies an ability to activate G proteins 32 which presumably requires an opening of
the intracellular crevice for G protein binding 33 as has been established in class A GPCRs.
Some conformationally selective ligands are capable of converting class A GPCRs into a
partially activated state where the change in the ligand binding pocket propagates into the
intracellular side of the receptors 34–38. In other cases, e.g. in β-adrenergic receptors, agonist
binding alone is insufficient for stabilization of an active state, and therefore in the structures
of these receptors obtained in the absence of G-proteins or their mimetics the intracellular
side maintains the inactive conformation 39,40. In the SAG1.5 bound SMO structure, we did
not observe the remodeling of the intracellular side which has been demonstrated in the
active state class A GPCR structures. This could be due to the following reasons: (i)
although SAG1.5 is a potent agonist for the canonical Hh signaling pathway, it is not an
effective agonist for G protein activation; (ii) the insertion of BRIL at ICL3 prevented
intracellular helical movement; and (iii) conformational changes at the intracellular part of
the receptor require binding of G proteins as observed for β-adrenergic receptors. Due to the
divergence of the canonical Hh signaling pathway from the traditional G protein pathway, it
is possible that the activated SMO couples to as yet unidentified intracellular effector(s),
which could eventually elicit conformational changes responsible for an active state.
Alternatively, activation by agonist might induce only small conformational changes in the
7TM domain, which modify oligomerization states or lead to differential association with
membrane compartments and intracellular trafficking machineries.
This long and narrow cavity responsible for the binding of small molecule ligands
investigated in this study is not the only modulation site for SMO. Lipid molecules have
been shown to be able to modulate SMO; for example, cholesterol depletion severely
impairs SMO activation 26. It has been suggested that the endogenous modulation
mechanism of SMO by Patched might also be mediated through a lipidic molecule 4.
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Oxysterols, for instance, have been shown to activate SMO and had been suspected to be
native ligands for SMO. However, recent studies showed that oxysterols bind to the N
terminal CRD domain (Fig. 5), the structure of which has been solved by crystallography27
and NMR41 methods, and that the CRD domain is important, but not essential, for the Hh-
induced activation of SMO as well as for cholesterol dependence of Hh signaling26–28.
Thus, there could be additional sites in the 7TM domain that serve as the binding sites of
native modulators or lipidic molecules. A previous study showed that mutations within the
ligand binding site that disrupt binding of synthetic ligands, such as cyclopamine, fail to
impair the normal basal and Hh-induced activity, as well as the cholesterol dependence of
Hh signaling 26, indicating an alternative site might be used to modulate SMO activity by
Patched or lipidic molecules. W3654.50 has been shown to be a conserved lipid binding site
at class A GPCRs 42–44, which locates at the interface between the 7TM domain and
membrane environment, and is thus accessible to lipidic molecules. In the agonist bound
structure, we observed conformational changes in a hydrogen bond network involving
W3654.50 (Supplementary Figure 6), which occur in the vicinity of W5357.55, a critical
residue for SMO activation. Further studies will be needed to fully investigate the role of
this region in the modulation of SMO by lipidic molecules.
In summary, we provide new insights into the conformational plasticity of SMO-ligand
interactions by crystallographic and biochemical characterization of several SMO complexes
with diverse ligand chemotypes. Importantly, these ligands target distinct sites in the
elongated cavity, have different interactions with known resistance mutants and include both
antagonists and agonists of Hh signaling. The details of these interactions and ligand-
dependent conformational changes, correlated with specific functional features of the
ligands will help to design new clinical candidates targeting SMO with attenuated side
effects and chemoresistance.
Methods
Generation of BRIL-SMO fusion constructs
The BRIL-ΔCRD-SMO-ΔC construct has been reported previously 14. For ΔCRD-SMO-
BRIL(ICL3)-ΔC, BRIL was fused to the human SMO receptor 7TM domain (S190-Q555)
by replacing ICL3 residues P434 to K440 using overlapping PCR. The resulting receptor
chimera sequence was subcloned into a modified pFastBac1 vector (Invitrogen), designated
as pFastBac1-833100, which contained an expression cassette with a haemagglutinin (HA)
signal sequence followed by a Flag tag, a 10× His tag, and a TEV protease recognition site
at the N terminus before the receptor sequence. Subcloning into the pFastBac1-833100 was
achieved using PCR with primer pairs encoding restriction sites KpnI at the 5′ and HindIII at
the 3′ termini with subsequent ligation into the corresponding restriction sites in the vector.
Expression and purification of SMO constructs
The SMO constructs were expressed in Spodoptera frugiperda (Sf9) insect cells using the
Bac-to-Bac Baculovirus Expression System (Invitrogen). Sf9 cells at cell density of 2–3 ×
106 cells/ml were infected with baculovirus at 27 °C. Cells were harvested by centrifugation
at 48 hr post infection and stored at −80 °C until use.
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Insect cell membranes were lysed by thawing frozen cell pellets in a hypotonic buffer
containing 10 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM KCl and EDTA-free complete
protease inhibitor cocktail tablets (Roche). Extensive washing of the raw membranes was
performed by repeated centrifugation two-three times in a high osmotic buffer comprised of
1.0 M NaCl in the hypotonic buffer described above.
The washed membranes were resuspended into buffer containing 30 µM ligand, 2 mg/ml
iodoacetamide (Sigma), and EDTA-free complete protease inhibitor cocktail tablets, and
incubated at 4 °C for 1 hr prior to solubilization. The membranes were then solubilized in
buffer containing 50 mM HEPES, pH 7.5, 200 mM NaCl, 1% (w/v) n-dodecyl-β-D-
maltopyranoside (DDM, Anatrace), 0.2% (w/v) cholesteryl hemisuccinate (CHS, Sigma), 15
µM ligand, for 3–4 hours at 4 °C. The supernatant containing solubilized SMO protein was
isolated from the cell debris by high-speed centrifugation, and subsequently incubated with
TALON IMAC resin (Clontech) overnight at 4 °C in the presence of 20 mM imidazole and
1 M NaCl. After binding, the resin was washed with 10 column volumes of Wash I Buffer
comprised of 50 mM HEPES, pH 7.5, 800 mM NaCl, 10% (v/v) glycerol, 0.1% (w/v) DDM,
0.02% (w/v) CHS, 8 mM ATP, 20 mM imidazole, 10 mM MgCl2 and 15 µM ligand,
followed by 6 column volumes of Wash II Buffer comprised of 50 mM HEPES, pH 7.5, 500
mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 50 mM imidazole and
20 µM ligand. The protein was then eluted by 3 column volumes of Elution Buffer
containing 50 mM HEPES, pH 7.5, 300 mM NaCl, 10% (v/v) glycerol, 0.03% (w/v) DDM,
0.006% (w/v) CHS, 250 mM imidazole and 50 µM ligand. PD MiniTrap G-25 column (GE
Healthcare) was used to remove imidazole. The protein was then treated overnight with
TEV protease (His-tagged) to cleave the N-terminal His-tag and FLAG-tag. TEV protease
and cleaved N-terminal fragment were removed by TALON IMAC resin incubation at 4 °C
for 2 hr. The tag-less protein was collected as the TALON IMAC column flow-through. The
protein was then concentrated to 50–60 mg/ml with a 100 kDa cut-off Vivaspin
concentrator. Protein monodispersity was tested by analytical size-exclusion
chromatography (aSEC). Typically, the aSEC profile showed a monodisperse peak.
SANT1 ligand was purchased from Tocris Biosciences (purity > 99%); Anta XV (originally
named Hh Signaling Antagonist XV) ligand was purchased from Calbiochem (purity
98.94%); and SAG1.5 ligand was purchased from Xcess Biosciences Inc. (purity > 98%).
Lipidic cubic phase crystallization
Protein samples of SMO in a complex with certain ligand were reconstituted into lipidic
cubic phase (LCP) by mixing with molten lipid (monoolein and cholesterol mixture in a
ratio of 9:1 (w/w)) in a mechanical syringe mixer 45. LCP crystallization trials were
performed using an NT8-LCP crystallization robot (Formulatrix) as previously described 46.
96-well glass sandwich plates (Marienfeld) were incubated and imaged at 20 °C using an
automated incubator/imager (RockImager 1000, Formulatrix). Crystals of SMO_SANT1
complex were grown in the condition: 150 mM NH4F, 100 mM HEPES pH 6.9, 27% PEG
400, 2.5% Jeffamine; crystals of SMO_Anta XV complex were grown in the condition:
100–115 mM NH4Cl, 100 mM HEPES pH 7.2, 36% PEG 400; and crystals of
SMO_SAG1.5 complex were grown in the condition: 100 mM MgSO4, 100 mM MES pH
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6.0, 30% PEG 400, 2%–3% Polypropylene glycol P 400. Crystals were harvested using
MiTeGen micromounts and flash frozen in liquid nitrogen for data collection.
Crystallographic data collection and processing
X-ray data were collected at the 23ID-D beamline (GM/CA CAT) at the Advanced Photon
Source, Argonne, IL using a 20 μm minibeam at a wavelength of 1.0330 Å and a MarMosaic
300 CCD detector. Crystals were aligned and data were collected using strategy similar to
other GPCR structures 47. Typically 20 frames at 1° oscillation and 1 s exposure with non-
attenuated beam followed by a translation of the crystal to a non-exposed position or
changing the crystal to minimize the effect of radiation damage. A complete data set was
obtained by indexing, integrating, scaling, and merging data using HKL2000 48. The
SMO_SAG1.5 data set was highly anisotropic. The merged data were submitted to the
UCLA anisotropy server (http://services.mbi.ucla.edu/anisoscale) and anisotropically
truncated at 2.9 Å, 2.5 Å and 3.3 Å along a*, b* and c* axes, respectively.
Structure determination and Refinement
Initial phase information was obtained by molecular replacement with the program
PHASER49 using two independent search models of SMO 7TM domain and BRIL from
SMO_LY2940680 complex structure (PDB id: 4JKV). All refinements were performed with
REFMAC550 and autoBUSTER51 followed by manual examination and rebuilding of the
refined coordinates in the program COOT52 using both |2FO|-|FC| and |FO|-|FC| maps, as well
as omit maps calculated using the Bhat’s procedure53,54. The structures have been deposited
in the PDB with the accession codes: 4N4W for SMO_SANT1 complex; 4QIM for
SMO_AntaXV complex; and 4QIN for SMO_SAG1.5 complex.
Radioligand competition
3H-Cyclopamine binding to WT and mutant SMO was done as previously described 9.
Molecular modeling and KAAD-cyclopamine docking
Conformational modeling and evaluation of the mutation effects in SMO complexes with
different ligands was performed using an all-atom global energy optimization algorithm in
ICM-Pro 3.7 (MolSoft LLC) molecular modeling package 55. Point mutations of interest
(L3253.36F, V3293.40F, I4085.47F, T4666.48Q) in each of the co-crystal structures were
introduced by modifying the residue side chain, followed by energy optimization that
included the ligand and side chains within 6 Å distance of the mutated residue. Other side
chains and the backbone of the protein were kept as in the crystal structure. The effect of the
mutation was evaluated by comparing conformational energy of the ligand before and after
mutation. Docking of KAAD-cyclopamine was performed with all atom energy-based
docking procedure with side chain flexibility in the binding pocket 56 using the
SMO_cyclopamine crystal structure. An initial conformation of KAAD-cyclopamine was
generated by Cartesian optimization of the ligand model in Merck Molecular Force Field.
All calculations were repeated at least in 3 independent runs, performed on a 12-core Intel
Xeon 2.67 GHz Linux workstation.
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Figure 1. Overall structures of SMO receptor bound to different ligands and the ligand binding
pockets
(a), (c) and (e) Overall structures of SMO receptor in complex with SANT1, Anta XV and
SAG1.5, respectively. The lipid bilayer is shown in dashed lines. The ligand binding cavity
is shown in surface presentation. SMO_SANT1 structure (yellow); SMO_Anta XV structure
(green); SMO_SAG1.5 structure (light blue) are shown in ribbon presentation. (b), (d) and
(f) The structures of the ligand binding pockets for SANT1 (orange carbon), Anta XV (green
carbon) and SAG1.5 (light blue carbon) are shown. Polar interactions between the receptor
and the ligands are shown as dashed lines and interacting residues are labeled.
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Figure 2. The deep binding pocket of SANT1
(a) Localization of different ligands in the binding pocket: SANT1 (orange), Anta XV
(green), SAG1.5 (light blue), LY2940680 (magenta), and cyclopamine (cyan). (b) and (c)
The shapes of the deep binding pockets in the structures of SMO_Anta XV (green) and
SMO_SANT1 (yellow), respectively. (d) Superposition of the deep binding pockets in the
structures of SMO_Anta XV and SMO_SANT1. The side chain movements induced by
SANT1 binding are shown by arrows. (e) ΔpKi values (pKi wild type – pKi mutants) of the
designed mutants for different SMO ligands in 3H-cyclopamine competition experiments.
Shown in the graph are mean ± SEM of 3–4 independent experiments, see also
Supplementary Table 1.
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Figure 3. D4736.55 plays different roles in the recognition of Anta XV and LY2940680
(a)–(i) The receptor structures in SMO_Anta XV, SMO_SANT1 and SMO_LY2940680
(PDB id: 4JKV, molecule A) complexes are shown in green, yellow and salmon,
respectively. Ligand structures of Anta XV, SANT1 and LY2940680 are shown in green,
orange and magenta carbons, respectively. (a) Superposition of SMO_LY2940680 and
SMO_Anta XV structures near ECL3. The conformational change of F484ECL3 induced by
LY2940680 binding is shown by an arrow. See also Supplementary Figure 4 for comparison
with SMO_SANT1 structure. (b) Superposition of the SMO_SANT1, SMO_Anta XV and
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SMO_LY2940680 structures reveals a different conformation of ECL3 in LY2940680
bound structure (shown by arrow). (c) Localization of ECL3 (green) and polar residue
cluster (R4005.39, D4736.55 and E5187.38, red) in SMO. (d) Superposition of the binding
poses of LY2940680 and Anta XV reveals distinct orientations (dashed lines parallel to the
equatorial bonds of the six-membered chair conformation rings) of the six membered rings
connected to the phthalazine ring. The shift of the phthalazine of LY2940680 compared to
that of Anta XV is shown by arrow. (e) Superposition of SMO_Anta XV and SMO_SANT1
structures. (f) Superposition of SMO_LY2940680 and SMO_SANT1 structures. (g)
Superposition of SMO_LY2940680 and SMO_Anta XV structures. Ligand induced shifts of
helices are shown by arrows. (h) Superposition of the ligand binding pocket residues of
SMO_SANT1, SMO_Anta XV and SMO_LY2940680 structures. Ligand interaction
induced conformation change at D4736.55 is indicated by arrow. (i) Polar residue cluster in
the ligand binding pocket of the SMO_Anta XV structure. Polar interactions are shown as
dashed lines. (j) ΔpKi values (pKi wild type– pKi mutants) of the D4736.55A and E5187.38A
mutants for different SMO receptor ligands in 3H-cyclopamine competition experiments.
Shown in the graph are mean ± SEM of 3–4 independent experiments, see also
Supplementary Table 2.
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Figure 4. Agonist SAG1.5 induced conformational changes in the ligand binding pocket
(a) Superposition of the ligand binding pocket residues of different structures of SMO. The
receptor structure and side chain carbons are shown for SMO_Anta XV (green),
SMO_SANT1 (yellow), SMO_LY2940680 (salmon; PDB id: 4JKV, molecule A), and
SMO_SAG1.5 (light blue) structures. The ligand SAG1.5 is shown as light blue carbons.
The hydrogen bond interactions between side chains are show as dashed lines in the
corresponding color of each structure. (b) A different view of the superposition of the ligand
binding pocket residues. H4706.52 which interacts with R4005.39 in antagonist bound
structures is shown. Red arrows (in (a) and (b)) are shown to indicate the conformational
changes of E5187.38 and R4005.39 induced by SAG1.5 binding. (c) Schematic presentation
of agonist induced conformation change: green is antagonist bound state, while blue is
agonist bound state.
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Figure 5. Map of the structural basis for the modulation of SMO by small molecules
The N terminal CRD domain is shown using the CRD of zebrafish SMO (PDB id: 4C79).
The boundaries of the membrane bilayer are shown as dashed lines.
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